Anti-Human CD20 Recombinant Antibody (Rituximab)

Customer Review

There are currently no Customer reviews or questions for TAB-016. Click the button above to contact us or submit your feedback about this product.

Q&As

1. Is the anti-Human CD20 therapeutic antibody Rituximab suitable for use in flow cytometry analysis?

   A: Yes, the anti-Human CD20 therapeutic antibody Rituximab (TAB-016) is suitable for use in flow cytometry analysis. It provides specific binding to CD20, allowing for the detection of CD20-expressing cells in flow cytometry assays.

2. What are the storage recommendations for the anti-Human CD20 therapeutic antibody Rituximab?

   A: The recommended storage condition for the anti-Human CD20 therapeutic antibody Rituximab (TAB-016) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-Human CD20 therapeutic antibody Rituximab be used in immunoprecipitation assays?

   A: Yes, the anti-Human CD20 therapeutic antibody Rituximab (TAB-016) can be used in immunoprecipitation assays. It provides specific binding to CD20, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-Human CD20 therapeutic antibody Rituximab effective in ELISA applications?

   A: Yes, the anti-Human CD20 therapeutic antibody Rituximab (TAB-016) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of CD20.

5. What is the optimal dilution for using the anti-Human CD20 therapeutic antibody Rituximab in immunofluorescence?

   A: The optimal dilution for using the anti-Human CD20 therapeutic antibody Rituximab (TAB-016) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Limongi, Tania, et al. "Extracellular vesicles tropism: A comparative study between passive innate tropism and the active engineered targeting capability of lymphocyte-derived evs." Membranes 11.11 (2021): 886. https://doi.org/10.3390/membranes11110886
   This study investigates the targeting capabilities of extracellular vesicles (EVs) derived from B lymphocytes. The researchers conducted a thorough immuno-phenotypic characterization of B-cell EV membranes and explored the tropism of these vesicles towards different cell lines. The study demonstrated that native EVs have an innate capability for passive targeting, which could be significantly enhanced by engineering the vesicles with anti-CD20 monoclonal antibodies. The engineered EVs showed increased internalization into target cancer cells, specifically Daudi cells, which highly express the CD20 marker, compared to HL60 cells that lack this marker.
   Creative Biolabs contributed significantly to this research by providing the anti-CD20 monoclonal antibody Rituximab (Cat#: TAB-016). This antibody was crucial for engineering the EVs to enhance their targeting capability towards CD20-expressing cancer cells. The use of this antibody allowed the researchers to demonstrate the increased efficacy of the engineered EVs in selectively targeting and internalizing into the Daudi cell line, thereby validating the potential of antibody-engineered EVs for targeted cancer therapy.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-016, RRID: AB_3111749)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "Rituximab"

Afuco™ Anti-MS4A1 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-016)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human CD20. It is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells (this should not be confused with pancreatic β- or beta cells).

See other products for "MS4A1"

Select a product category from the dropdown menu below to view related products.

Chimeric Antibodies Mouse Antibodies Humanized Antibodies IgG Antibodies Human Antibodies Fc Glycosylation Antibodies Low- or Non-fucosylated Oligosaccharide Antibodies Hyper-galactosylated Antibodies High-mannose Glycoform Antibodies Deglycosylated Antibodies MHC Tetramers for Cancer Neutralizing Antibodies Rabbit Monoclonal Antibodies ScFv Antibodies Fab Antibodies Single Domain Antibodies ADCC Enhanced Antibodies Antibody Magnetic Beads Hexamer Antibodies NHP Antibodies ScFv-Fc Chimeras FC Reagents & Kits Extracellular Vesicle Antibodies IHC Kits & Antibodies Biparatopic Antibodies